Global Leading Market Research Publisher QYResearch announces the release of its latest report "Immunotoxicity Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". In pharmaceutical and biotechnology development, ensuring that novel therapeutics do not compromise immune system function remains a critical safety imperative. Drug developers face persistent challenges in identifying potential adverse immune effects—including immunosuppression, immunostimulation, hypersensitivity, and cytokine storm responses—early in development to avoid costly late-stage failures and regulatory setbacks. This report quantifies the market trajectory of immunotoxicity testing, specialized safety assessment services that evaluate the interaction of drug candidates, biologics, and medical device materials with the immune system.

The global market for Immunotoxicity Testing was estimated to be worth US$ 5,538 million in 2025 and is projected to reach US$ 12,610 million, growing at a CAGR of 12.7% from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097976/immunotoxicity-testing

Defining the Service: Comprehensive Immune Safety Evaluation
Immunotoxicity testing is the evaluation of whether a substance—such as a drug, biologic, chemical, or medical device material—interferes with the normal function, regulation, or integrity of the immune system. It identifies potential adverse immune effects, including suppression, stimulation, hypersensitivity, autoimmunity, or cytokine storm–like responses. These assessments are essential for regulatory submissions to agencies including the FDA, EMA, and PMDA, forming a critical component of nonclinical safety packages for investigational new drug (IND) and new drug application (NDA) filings.

Market Segmentation: In Vivo vs. In Vitro Testing
The Immunotoxicity Testing market is segmented by methodology into in vivo testing and in vitro testing. In vivo testing—conducted in animal models—represents the established standard for regulatory immunotoxicity assessment, encompassing T-cell dependent antibody response (TDAR) assays, natural killer cell activity assessment, and host resistance studies. These approaches provide integrated assessment of immune function across multiple cell types and organ systems.

In vitro testing represents the fastest-growing segment, driven by the 3Rs (replacement, reduction, refinement) movement in animal testing, increasing complexity of novel therapeutic modalities, and demand for higher-throughput screening. This segment encompasses flow cytometry-based immunophenotyping, cytokine release assays, T-cell activation assays, and dendritic cell function assessments. The adoption of human cell-based in vitro systems has accelerated for biologics and cell therapies where species-specific responses limit the predictive value of animal models.

Application Landscape: Biotechnology, Pharmaceutical Industry, and Emerging Segments
From an application perspective, the market serves three primary domains. The biotechnology sector represents the fastest-growing segment, driven by the proliferation of novel modalities including monoclonal antibodies, bispecifics, antibody-drug conjugates (ADCs), cell and gene therapies, and RNA therapeutics. These complex modalities require specialized immunotoxicity assessment strategies tailored to their unique mechanisms of action and potential for immune-mediated adverse events.

The pharmaceutical industry represents the largest revenue segment, encompassing small molecule drug development where immunotoxicity assessment focuses on potential for immunosuppression, hypersensitivity, and autoimmune responses. The "others" category encompasses medical device materials, industrial chemicals, and environmental toxicology applications.

Competitive Landscape: Global CROs and Specialized Immunotoxicology Providers
The competitive landscape features established global contract research organizations (CROs) with specialized immunotoxicology capabilities. Charles River Laboratories, Eurofins, and IQVIA dominate the premium segment, offering integrated nonclinical safety assessment services spanning immunotoxicity testing, general toxicology, and regulatory submission support.

Specialized providers including Altasciences, BioAgilytix, BRT Laboratories, Intertek, and Nelson Labs command significant share in niche segments such as cytokine release assays, immunophenotyping, and Good Laboratory Practice (GLP)-compliant immunotoxicity testing for biologics and cell therapies.

Industry Deep-Dive: Biologic Pipeline Expansion and Testing Complexity
Over the past six months, the industry has witnessed accelerated demand driven by three converging factors. First, the biologics pipeline has reached unprecedented scale, with over 1,200 biologic candidates in late-stage development as of Q4 2025. The complexity of these molecules—including novel scaffolds, multi-specific formats, and conjugated modalities—has increased immunotoxicity testing requirements, with each candidate requiring customized assay strategies.

Second, the cell and gene therapy (CGT) pipeline has intensified demand for specialized immunotoxicity assessment. A recent case study from a late-stage CAR-T developer revealed that immunotoxicity testing for cytokine release syndrome (CRS) risk assessment required a multi-tiered strategy combining in vitro cytokine release assays, in vivo xenograft models, and translational biomarker analysis—representing a 40% increase in testing scope compared to conventional biologics.

Third, regulatory expectations for immunotoxicity assessment have continued to evolve. The FDA's 2025 guidance on "Immunotoxicity Assessment for Cell and Gene Therapy Products" emphasized the importance of evaluating potential for off-target immune activation, including assessment of cytokine release, complement activation, and immunogenicity risk. This guidance has driven increased investment in specialized testing capabilities among CROs.

Exclusive Insight: Divergence Between Small Molecule and Biologic Immunotoxicity Testing
A distinct pattern emerges when comparing testing requirements across therapeutic modalities. Small molecule immunotoxicity assessment typically follows established ICH S8 guidelines, with emphasis on TDAR assays and immunophenotyping in rodent models. The testing paradigm is relatively standardized, with focus on immunosuppression and hypersensitivity risk.

In contrast, biologic and CGT immunotoxicity assessment requires customized, modality-specific strategies. Monoclonal antibodies require assessment of cytokine release risk, particularly for T-cell engaging formats. ADCs require evaluation of immunogenicity and potential for off-target immune activation. Cell therapies require comprehensive assessment of cytokine release, on-target/off-tumor effects, and potential for graft-versus-host disease.

This divergence has strategic implications for CROs. Those serving small molecule developers must demonstrate regulatory expertise and GLP compliance for established testing paradigms. Those focused on biologics and CGT must invest in specialized capabilities including human cell-based assays, flow cytometry platforms, and translational biomarker expertise.

Technical Barriers and Innovation Frontiers
Cytokine release assessment remains a critical technical challenge, with standard in vitro assays showing limited predictive value for clinical cytokine release syndrome. CROs are increasingly implementing co-culture systems with human immune cells and endothelial cells to better recapitulate physiological conditions.

Another frontier is the application of high-dimensional immunophenotyping and single-cell technologies. These approaches enable comprehensive characterization of drug effects on immune cell populations, with potential to identify safety signals earlier in development. CROs are investing in mass cytometry and single-cell RNA sequencing capabilities to support advanced immunotoxicity assessment.

Future Outlook: Sustained Growth Through Biologic Pipeline Expansion
Looking toward 2032, the market is poised for sustained growth at a 12.7% CAGR, reaching US$12.6 billion. Key catalysts include continued expansion of the biologics and CGT pipelines, increasing complexity of novel therapeutic modalities requiring specialized testing strategies, and sustained outsourcing trends among emerging biotech developers. CROs that can deliver integrated immunotoxicity assessment solutions combining regulatory expertise, specialized assay capabilities, and translational insights will capture disproportionate market share.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp